DOTA Zoledronate
DOTA Zoledronate is a next-generation agent for bone targeted radionuclide therapy for diagnosing bone metastases[1].
Product Specifications
CAS Number
1908409-18-6
UNSPSC
12352005
Target
Radionuclide-Drug Conjugates (RDCs)
Type
Reference compound
Related Pathways
Antibody-drug Conjugate/ADC Related
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/dota-zoledronate.html
Solubility
10 mM in DMSO
Smiles
O=C(CN1CCN(CCN(CCN(CC1)CC(O)=O)CC(NCCC2=CN(CC(P(O)(O)=O)(O)P(O)(O)=O)C=N2)=O)CC(O)=O)O
Molecular Formula
C23H41N7O14P2
Molecular Weight
701.56
References & Citations
[1]The ITM Group Announces In-Licensing of DOTA-Zoledronate Theranostic Agent.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
108900R1-AAT 500 Tests
IFluor® 860 Anti-human/ non-human primates CD89 Antibody *A59*
Sign In for Pricing
View Details 
K0065608 1.0 µg DNA
AKAP3 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 3)
Sign In for Pricing
View Details